IL186104A - Phosphoramidate History of Nucleoside Compounds - Google Patents

Phosphoramidate History of Nucleoside Compounds

Info

Publication number
IL186104A
IL186104A IL186104A IL18610407A IL186104A IL 186104 A IL186104 A IL 186104A IL 186104 A IL186104 A IL 186104A IL 18610407 A IL18610407 A IL 18610407A IL 186104 A IL186104 A IL 186104A
Authority
IL
Israel
Prior art keywords
cancer
treatment
processes
preparation
pharmaceutical compositions
Prior art date
Application number
IL186104A
Other languages
English (en)
Hebrew (he)
Other versions
IL186104A0 (en
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Nucana Biomed Ltd
Univ Cardiff
Cardiff Protides Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher Mcguigan, Kenneth Mills, Costantino Congiatu, Nucana Biomed Ltd, Univ Cardiff, Cardiff Protides Ltd filed Critical Christopher Mcguigan
Publication of IL186104A0 publication Critical patent/IL186104A0/en
Publication of IL186104A publication Critical patent/IL186104A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL186104A 2005-03-21 2007-09-20 Phosphoramidate History of Nucleoside Compounds IL186104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
IL186104A0 IL186104A0 (en) 2008-01-20
IL186104A true IL186104A (en) 2013-06-27

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186104A IL186104A (en) 2005-03-21 2007-09-20 Phosphoramidate History of Nucleoside Compounds

Country Status (20)

Country Link
US (1) US8263575B2 (enExample)
EP (1) EP1866324B1 (enExample)
JP (2) JP5345381B2 (enExample)
CN (2) CN103936807A (enExample)
AT (1) ATE471334T1 (enExample)
AU (1) AU2006226182C1 (enExample)
BR (1) BRPI0609704B8 (enExample)
CA (1) CA2602324C (enExample)
CY (1) CY1111538T1 (enExample)
DE (1) DE602006014949D1 (enExample)
DK (1) DK1866324T3 (enExample)
ES (1) ES2348741T3 (enExample)
GB (1) GB0505781D0 (enExample)
IL (1) IL186104A (enExample)
MX (1) MX2007011666A (enExample)
PL (1) PL1866324T3 (enExample)
PT (1) PT1866324E (enExample)
SI (1) SI1866324T1 (enExample)
WO (1) WO2006100439A1 (enExample)
ZA (1) ZA200709011B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
EA026341B9 (ru) 2010-03-31 2021-12-27 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Кристаллическая форма нуклеозидфосфорамидата
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012092484A2 (en) * 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
EP3235824B1 (en) 2012-11-16 2019-03-27 University College Cardiff Consultants Limited Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
AU2014354775A1 (en) 2013-11-27 2016-05-19 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
RU2016149761A (ru) * 2014-05-28 2018-07-02 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Производные нуклеозидов для лечения ракового заболевания
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
HRP20191461T1 (hr) 2014-11-28 2019-11-15 NuCana plc Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
BR112018009946A8 (pt) * 2015-11-16 2019-02-26 Ichorion Therapeutics Inc pró-fármacos de ácido nucleico
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
WO2018071675A1 (en) * 2016-10-12 2018-04-19 Georgetown University Cd99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) * 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DK0821692T3 (da) 1995-04-21 2006-05-22 Univ South Florida Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
US6245750B1 (en) * 1998-01-23 2001-06-12 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
KR20050059975A (ko) * 2001-06-22 2005-06-21 파마셋 인코포레이티드 β-2'- 또는 3'-할로뉴클레오시드
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Also Published As

Publication number Publication date
CA2602324A1 (en) 2006-09-28
AU2006226182A1 (en) 2006-09-28
BRPI0609704B1 (pt) 2020-12-01
AU2006226182B2 (en) 2011-09-01
US20090215715A1 (en) 2009-08-27
JP2008533191A (ja) 2008-08-21
PT1866324E (pt) 2010-09-16
IL186104A0 (en) 2008-01-20
DE602006014949D1 (de) 2010-07-29
BRPI0609704A2 (pt) 2010-04-20
SI1866324T1 (sl) 2010-10-29
JP2013173786A (ja) 2013-09-05
JP5863702B2 (ja) 2016-02-17
CN101175763A (zh) 2008-05-07
ES2348741T3 (es) 2010-12-13
ATE471334T1 (de) 2010-07-15
DK1866324T3 (da) 2010-09-27
AU2006226182C1 (en) 2012-06-14
GB0505781D0 (en) 2005-04-27
JP5345381B2 (ja) 2013-11-20
WO2006100439A1 (en) 2006-09-28
CA2602324C (en) 2015-02-24
US8263575B2 (en) 2012-09-11
PL1866324T3 (pl) 2010-12-31
CY1111538T1 (el) 2015-08-05
EP1866324B1 (en) 2010-06-16
BRPI0609704B8 (pt) 2021-09-28
CN103936807A (zh) 2014-07-23
MX2007011666A (es) 2007-11-14
EP1866324A1 (en) 2007-12-19
ZA200709011B (en) 2009-01-28

Similar Documents

Publication Publication Date Title
IL186104A (en) Phosphoramidate History of Nucleoside Compounds
TW200736262A (en) Heteroalkyl linked pyrimidine derivatives
IL204732A (en) @@@@@ - Diplooro - @@ - Deoxy @ tetrahydro uridines, preparations containing them and their use in making @ drugs
MX2022008744A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
MX2009010047A (es) Compuestos quimicos.
MY145447A (en) Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
MY146112A (en) Long-term feed - cancer patient
TW200716646A (en) (S)-N-methylnaltrexone
MX2009010045A (es) Compuestos quimicos.
MY143795A (en) Tetrahydropyridoindole derivatives
IL170834A (en) Imidazo-pyridine derivatives and their use as medicaments
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
TW200738659A (en) Novel compounds
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CL2008003933A1 (es) Compuestos derivados de n-heterociclo-[1,2-a]-piridina-2-carboxamida; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
IL192454A (en) Solid Pharmaceuticals Containing S-Adenosylmethionine
SE0300457D0 (sv) Novel compounds
IL178939A (en) Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
NO20085189L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamid-benzotaizepiner, fremstilling og anvendelse derav sammensetninger inneholdende samme
WO2007052300A3 (en) Processes for the preparation of different forms of (s)-(+)-clopidogrel besylate
WO2010146370A3 (en) Sox11 activating agents and uses thereof
DE602007009396D1 (en) Camptothecinderivate mit antitumorwirkung

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed